- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MBI ends Albunex dispute with Shionogi
Molecular Biosystems of San Diego has settled a dispute with Shionogi& Co. of Osaka, Japan, over Asian distribution of MBI's Albunexultrasound contrast agent (SCAN 3/27/96). MBI has agreed to payShionogi $3 million now and another $5.5 million over
Molecular Biosystems of San Diego has settled a dispute with Shionogi& Co. of Osaka, Japan, over Asian distribution of MBI's Albunexultrasound contrast agent (SCAN 3/27/96). MBI has agreed to payShionogi $3 million now and another $5.5 million over the nextthree years to reacquire licensing rights in the Asia-Pacificregion.
Shionogi is the second regional licensee to reject rights to Albunex,which has had a rocky launch. Late last year, Norwegian contrastdeveloper Nycomed turned over to MBI the European rights to Albunex,which is known in Europe as Infoson (SCAN 3/13/96).
Sales of Albunex in Japan were slower than anticipated since theproduct was approved there in 1993. In their dispute, MBI claimedthat Shionogi did not diligently pursue the development and distributionof Albunex in its territory, while Shionogi countered with claimsthat MBI supplied it with batches of Albunex that were of inferiorquality.
MBI has been actively searching for a new licensee to handle Asia-Pacificsales of Albunex, according to the company.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
